Editas Medicine Announces Poster Presentations at the European Society of Gene and Cell Therapy (ESGCT) 33rd Annual Congress and Participation in Upcoming Investor Conference

CAMBRIDGE, Mass., Oct. 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced two poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 33(rd) Annual Congress, to be held October 27-30, 2026, in Hamburg, Germany. * European Society of Gene and Cell Therapy (ESGCT) Congress Title: Novel targeted LNP delivery achieved in vivo CAR-T cell generation resulting in therapeutically relevant B-cell depletion Session Date and Time: Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET Session Title: Poster Session 1 Presenter: Harry An, Director, Process Development, Editas Medicine Final Abstract Number: P0361

Title: Development of a configurable, GMP-ready manufacturing platform for targeted LNP therapeutics Session Date and Time: Wednesday, October 28, 2026, 1:30 - 3:30 p.m. CET Session Title: Poster Session 1 Presenter: Harry An, Director, Process Development, Editas Medicine Final Abstract Number: P0781 Abstracts can be accessed on the conference website as they become available, and presentations will also be posted to the “Posters & Presentations” section of the Company’s website during the conferences.